704 related articles for article (PubMed ID: 23522121)
21. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
25. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
26. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.
Stonehouse A; Walsh B; Cuddihy R
Diabetes Technol Ther; 2011 Oct; 13(10):1063-9. PubMed ID: 21732798
[TBL] [Abstract][Full Text] [Related]
27. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
28. Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
Busch RS; Ruggles J; Han J; Hardy E
Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29044860
[TBL] [Abstract][Full Text] [Related]
29. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
32. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
[TBL] [Abstract][Full Text] [Related]
33. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
34. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
[TBL] [Abstract][Full Text] [Related]
35. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
36. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
[TBL] [Abstract][Full Text] [Related]
37. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR; Klein EJ; Han J; Iqbal N
Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
40. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Arnolds S; Dellweg S; Clair J; Dain MP; Nauck MA; Rave K; Kapitza C
Diabetes Care; 2010 Jul; 33(7):1509-15. PubMed ID: 20357372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
